Publications en collaboration avec des chercheurs de Hospital Miguel Servet (15)

2024

  1. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

    Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

  2. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731

2022

  1. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  2. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

2020

  1. Safety and effectiveness of aflibercept + fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) in current clinical practice: OZONE study

    Cancers, Vol. 12, Núm. 3

2019

  1. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer

    Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329

2015

  1. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

  2. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

  3. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 972-981

2014

  1. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status

    Angiogenesis, Vol. 17, Núm. 4, pp. 805-821

2010

  1. SEOM clinical guidelines for the treatment of advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 729-734